Bibliography
- Peng X, Zeng X, Peng S, The association risk of male subfertility and testicular cancer: a systematic review. PLoS One 2009;4:e5591
- Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol 2005;174:1819-22
- Kronenberg HM, Larsen PR, editor, Williams textbook of endocrinology. 11th edition. Saunders; 7 A.D
- McCullagh DR. Dual endocrine activity of the testes. Science 1932;76:19-20
- Zirkin BR, Awoniyi C, Griswold MD, Is FSH required for adult spermatogenesis? J Androl 1994;15:273-6
- Rogol AD. New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother 2005;6:1319-36
- Mauras N, Hayes V, Welch S, Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886-92
- Bhasin S, Bagatell CJ, Bremner WJ, Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998;83:3435-48
- Morley JE, Kaiser FE, Perry HM III, Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-3
- Bhasin S, Cunningham GR, Hayes FJ, Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995-2010
- Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on management of intersex disorders. J Pediatr Urol 2006;2:148-62
- Ambler GR. Androgen therapy for delayed male puberty. Curr Opin Endocrinol Diabetes Obes 2009;16:232-9
- Bertelloni S, Dati E, Baroncelli GI. Disorders of sex development: hormonal management in adolescence. Gynecol Endocrinol 2008;24:339-46
- Walvoord E. Sex steroid replacement for induction of puberty in multiple pituitary hormone deficiency. Pediatr Endocrinol Rev 2009;6(Suppl 2):298-305
- Pozo J, Argente J. Ascertainment and treatment of delayed puberty. Horm Res 2003;60(Suppl 3):35-48
- Mauras N, Haymond MW, Darmaun D, Calcium and protein kinetics in prepubertal boys. Positive effects of testosterone. J Clin Invest 1994;93:1014-9
- Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14:49-61
- Nieschlag E, Buchter D, von ES, Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999;51:757-63
- Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000;164:371-5
- Steidle C, Schwartz S, Jacoby K, AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-81
- Wang C, Cunningham G, Dobs A, Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-98
- Pope HG Jr, Cohane GH, Kanayama G, Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:105-11
- McNicholas TA, Dean JD, Mulder H, A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91:69-74
- Wang C, Swerdloff RS, Iranmanesh A, Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001;54:739-50
- Snyder PJ. Effects of age on testicular function and consequences of testosterone treatment. J Clin Endocrinol Metab 2001;86:2369-72
- Coward RM, Simhan J, Carson CC III. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 2009;103:1179-83
- Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415-24
- Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv 2008;5:471-81
- Meikle AW, Mazer NA, Moellmer JF, Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992;74:623-8
- ANDROGEL. Solvay Pharmaceuticals, 2009. Available from: http://www.solvaypharmaceuticals.com/Products/group/product/0,,30643-2-0,00.htm. [Last accessed 9 November 2009]
- Bentley Granted European Patent for Its Testosterone Gel. Business Wire, 2007. Available from: http://www.allbusiness.com/legal/intellectual-property-law/5249773-1.html. [Last accessed 9 November 2009]
- Androgel (Testosterone Gel for Topical Use) Drug Information. RxList, 2009. Available from: http://www.rxlist.com/androgel-drug.htm. [Last accessed 22 November 2009]
- Wang C, Berman N, Longstreth JA, Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85:964-9
- Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotrophic hypogonadism? Clin Endocrinol (Oxf) 2009. [Epub ahead of print]
- de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009;24:425-8
- Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988;319:1563-7
- Wang C, Swerdloff R, Kipnes M, New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004;89:3821-9
- STRIANT – Professional – STRIANT Patient Booklet. STRIANT Patient Booklet, 2010. Available from: http://www.striant.com/Professional/patient_booklet/patient_booklet.asp#FAQs. [Last accessed 6 January 2010]
- Kelleher S, Conway AJ, Handelsman DJ. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. Eur J Endocrinol 2002;146:513-8
- Kinniburgh D, Zhu H, Cheng L, Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 2002;17:1490-501
- Cavender RK, Fairall M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis. J Sex Med 2009;6:3177-92
- Acrux Announces Axiron Phase III Results. Wireless News Newspaper, 2010. Available from: http://findarticles.com/p/news-articles/wireless-news/mi_hb5558/is_20091003/acrux-announces-axiron-phase-iii/ai_n39986194. [Last accessed 30 December 2010]
- News: Acrux' Testosterone Treatment Triumphs in Phase III Study. Genetic Engineering & Biotechnology News, 2010. Available from: http://www.genengnews.com/news/bnitem.aspx?name=64091122. [Last accessed 26 November 2009]
- Axiron Fact Sheet 2009. www acrux com au, 2010. Available from: http://www.acrux.com.au/IRM/Company/ShowPage.aspx?CPID=1417. [Last accessed 14 January 2010]
- Available from: http://xpil.medicines.org.uk/ViewPil.aspx?DocID=19703. medicines org uk, 2010. [Last accessed 14 January 2010]
- Barrio R, de LD, Alonso M, Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril 1999;71:244-8
- Warne DW, Decosterd G, Okada H, A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009;92:594-604
- Vicari E, Mongioi A, Calogero AE, Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism–long-term follow-up. Int J Androl 1992;15:320-9
- Gordon D, Lauder JC, Cohen HN, An evaluation of human chorionic gonadotrophin (HCG) therapy in boys with delayed puberty. Q J Med 1990;74:247-56
- de Ronde W. Therapeutic uses of aromatase inhibitors in men. Curr Opin Endocrinol Diabetes Obes 2007;14:235-40
- Pavlovich CP, King P, Goldstein M, Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 2001;165:837-41
- Odame I, Donaldson MD, Wallace AM, Early diagnosis and management of 5 alpha-reductase deficiency. Arch Dis Child 1992;67:720-3
- Charmandari E, Dattani MT, Perry LA, Kinetics and effect of percutaneous administration of dihydrotestosterone in children. Horm Res 2001;56:177-81
- Wang C, Iranmanesh A, Berman N, Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men–a clinical research center study. J Clin Endocrinol Metab 1998;83:2749-57
- Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006;18:201-5
- Arrigo T, Cisternino M, Luca DF, Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J Pediatr Endocrinol Metab 1996;9:511-7
- Buyukgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995;44(Suppl 3):32-4
- Caruso-Nicoletti M, De Sanctis V, Raiola G, No difference in pubertal growth and final height between treated hypogonadal and non-hypogonadal thalassemic patients. Horm Res 2004;62:17-22
- Professional - STRIANT Prescribing Information. STRIANT,2010. Available from: http://www.striant.com/Professional/prescribing_info/prescribing_info.asp. [Last accessed 14 January 2010]
- Depo®-Testosterone, testosterone cypionate injection, USP. Pfizer,2010. Available from: http://www.pfizer.com/files/products/uspi_depo_testosterone.pdf. [Last accessed 14 January 2010]
- Nebido: Summary of Product Characteristics (SPC). emc medicines org uk,2010. Available from: http://emc.medicines.org.uk/ medicine/15661/SPC/Nebido+ 1000mg+4ml,+solution+for+injection# PHARMACOKINETIC_PROPS. [Last accessed 14 January 2010]
- Testopel: Prescription Drug Information, Side Effects. PDRHealth,2010. Available from: http://www.pdrhealth.com/drugs/rx/ rx-mono.aspx?contentFileName= tes1595.html&contentName=Testopel& contentId=754. [Last accessed 14 January 2010]
- Jockenhovel F, Vogel E, Kreutzer M, Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 1996;45:61-71